Autolus Therapeutics plc
AUTL· Nasdaq
AUTLAutolus Therapeutics plc
Source filing unavailable
derived · Computed from the longer spans the company filed.
| Metric | Q4 2019dderived from reported figures | Q4 2018 |
|---|---|---|
| Revenue | $309.00K | $296.00K |
| Net Income | -$40.94M | -$20.65M |
| EPS Diluted | — | -$0.52 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Autolus Therapeutics plc · CIK 1730463 · Engraved from SEC EDGAR
